Texas Capital Bancshares Inc is a registered bank holding company and a full-service financial services firm that delivers customized solutions to businesses, entrepreneurs and individual customers... Show more
The Aroon Indicator for TCBIO entered a downward trend on April 01, 2025. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 159 similar instances where the Aroon Indicator formed such a pattern. In of the 159 cases the stock moved lower. This puts the odds of a downward move at .
The Momentum Indicator moved below the 0 level on March 26, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on TCBIO as a result. In of 75 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for TCBIO turned negative on March 21, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 38 similar instances when the indicator turned negative. In of the 38 cases the stock turned lower in the days that followed. This puts the odds of success at .
TCBIO moved below its 50-day moving average on March 20, 2025 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TCBIO crossed bearishly below the 50-day moving average on March 13, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TCBIO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
The RSI Indicator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where TCBIO advanced for three days, in of 232 cases, the price rose further within the following month. The odds of a continued upward trend are .
TCBIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: TCBIO's P/B Ratio (0.000) is slightly lower than the industry average of (1.033). P/E Ratio (0.000) is within average values for comparable stocks, (17.147). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.366). Dividend Yield (0.072) settles around the average of (0.059) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (2.927).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. TCBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TCBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 59, placing this stock worse than average.
Industry RegionalBanks
A.I.dvisor indicates that over the last year, TCBIO has been loosely correlated with HBANP. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if TCBIO jumps, then HBANP could also see price increases.
Ticker / NAME | Correlation To TCBIO | 1D Price Change % | ||
---|---|---|---|---|
TCBIO | 100% | +0.10% | ||
HBANP - TCBIO | 51% Loosely correlated | +0.24% | ||
HBANL - TCBIO | 50% Loosely correlated | -0.00% | ||
CMA - TCBIO | 50% Loosely correlated | -1.46% | ||
VLYPP - TCBIO | 50% Loosely correlated | +0.41% | ||
HONE - TCBIO | 50% Loosely correlated | +1.16% | ||
More |